Pfizer’s Debt figure was $61 Bil at the end of the most recent quarter, while its market capitalization is $133 Bil (as of 6/2/2025). This implies a poor Debt-to-Equity Ratio of 46.2% (vs. 19.9% ...

COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. Fourteen months after an old tweet ...

Pfizer implemented a warranty programme that provided money back to insurers if the treatment did not work as expected, but it seems that was not enough to encourage uptake – despite the high ...

The past three years have been challenging for Pfizer (NYSE: PFE).Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022.

The past three years have been challenging for Pfizer (PFE 1.14%). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022.

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. | Pfizer's Braftovi, combined with Eli Lilly's Erbitux and chemo ...

Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and Mylan. With fewer older medications and fewer patent losses, Pfizer is ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers. The branded pharmaceutical industry relies on a ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, data that could change how physicians treat a particularly deadly form of ...